Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VENICE I: Venetoclax Monotherapy in Relapsed/Refractory CLL
2015-003667-11Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by AbbVie Inc. Primary endpoint: Complete remission rate (CR + CRi) in non-BCRi pretreated subjects. Started Jun 2016; status: completed.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2015-003667-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003667-11.